Hosted on MSN1d
A new anti-malaria ‘stealth weapon’ could be huge for US military deployments
Scientists made an incredible discovery not only treats malaria but takes down even the most drug-resistant parasites while ...
I was prescribed an antibiotic I didn't even need. Now I'm paralyzed
When Mateo Ramirez's doctor gave him the antibiotic ciprofloxacin to treat his stomach bug, he had no idea he would become ...
Medscape2d
Recommendations and Rationale for the Treatment of Pelvic Inflammatory Disease
Antibiotic regimens prospectively studied with little to no activity against anaerobic bacteria have uniformly performed well, while regimens containing metronidazole and doxycycline, which should ...
New Atlas1d
FDA approves new class of painkiller – the first in more than 20 years
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
aha.org1d
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
BioSpace1d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Business Wire2d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...
FDA approves first new class of painkiller in 20 years, a non-addictive opioid alternative
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
pharmaphorum4d
NewAmsterdam goes public to advance drug in abandoned class
the general consensus was that the drug class was an R&D dead end. Merck's exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following ...